Release Details

REGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare Conference

Aug 01, 2023 at 4:05 PM EDT

ROCKVILLE, Md., Aug. 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host one-on-one investor meetings at the 2023 Wedbush PacGrow Healthcare Conference on Tuesday, August 8, 2023.

2023 Wedbush PacGrow Healthcare Conference
Date: Tuesday, August 8, 2023


REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from its internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

Chris Brinzey
ICR Westwicke

(PRNewsfoto/REGENXBIO Inc.)


Cision View original content to download multimedia:



Contact Us